Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
To determine the effects of 12 weeks administration of different dose levels of ALV003 on the
mucosal lining of the small intestine and symptoms in celiac disease patients.